In this article, a framework for an in silico pipeline is presented as a guide to high-throughput vaccine candidate discovery for eukaryotic pathogens, such as helminths and protozoa. Eukaryotic pathogens are mostly parasitic and cause some of the most damaging and difficult to treat diseases in humans and livestock. Consequently, these parasitic pathogens have a significant impact on economy and human health. The pipeline is based on the principle of reverse vaccinology and is constructed from freely available bioinformatics programs. There are several successful applications of reverse vaccinology to the discovery of subunit vaccines against prokaryotic pathogens but not yet against eukaryotic pathogens. The overriding aim of the pipeline, which focuses on eukaryotic pathogens, is to generate through computational processes of elimination and evidence gathering a ranked list of proteins based on a scoring system. These proteins are either surface components of the target pathogen or are secreted by the pathogen and are of a type known to be antigenic. No perfect predictive method is yet available; therefore, the highest-scoring proteins from the list require laboratory validation.
INTRODUCTION
After almost a century of laboratory culture-based approaches to vaccine discovery, researchers are beginning to capitalize on the vast potential ofomics data (genomes, transcriptomes and proteomes) to make an in silico approach to vaccine discovery possible, without the need to cultivate the pathogen. Eukaryotic pathogens are extremely complicated systems with multifaceted life cycles. The key challenge of this in silico approach is how best to transform mere biological abstractions of complex systems (in the form of digital information) into the knowledge required to identify vaccine candidates.
In 2000, Rino Rappuoli [1] first proposed the idea of mining biological data to predict antigens that are most likely to be vaccine candidates. Effectively, the wet laboratory in the traditional culture-based approach to cultivate, dissect and identify antigens is replaced by a computer. His approach has been widely accepted as a way of discovering vaccines and is referred to as 'Reverse Vaccinology' on account that in its basic form, the approach starts with the genome of the pathogen rather than the pathogen itself. There are several successful applications of reverse vaccinology to the discovery of subunit vaccines against prokaryotic pathogens [2] [3] [4] [5] [6] .
The key to subunit vaccine development is the successful identification of molecules of a pathogen, as opposed to using the entire entity, which evoke a safe immune response. The candidate molecules from a eukaryotic pathogen expected to induce immunity comprise proteins that are as follows: (i) present on the surface of the pathogen, (ii) excreted/ secreted from the pathogen and (iii) homologous to
Stephen Goodswen did his research for MSc at CSIRO while enrolled at the University of New England. He is now pursuing a PhD at the University of Technology Sydney focusing on an in silico vaccine discovery pipeline for parasitic protozoa. Paul Kennedy obtained his PhD in Computing Science at the University of Technology, Sydney, in 1999 where he currently directs the Knowledge Infrastructure Laboratory in the Centre for Quantum Computation and Intelligent Systems. His interests involve data mining of biomedical data, particularly visualization and classification of childhood cancer patients using their systems biology. John Ellis has research interests focused on translational research that includes development of vaccines and diagnostics for parasitic diseases of economic importance. For the past 20 years, he has studied parasitic protozoa of both veterinary and medical importance and in recent times has broadened his interests to environmental protozoology and groundwater. known proteins involved in pathogenesis and virulence [7] . Some carbohydrates and lipids are also known to induce immunity. However, from a bioinformatics perspective, these molecules are much more computationally challenging to represent in a digital form than proteins and as a consequence are not dealt with in the pipeline.
The foremost advantage of reverse vaccinology is that the genome holds the entire repertoire of genes, which the pathogen can potentially express as protein antigens. The traditional culture-based approach only captures a subset of this entire repertoire for further laboratory investigation. This is because the expression of proteins is often governed by many factors. For example, the proteins expressed by a pathogen will be different in vivo, in vitro, in a particular life cycle stage and in response to host interactions, which may not be reproducible in vitro. It is thought that in the traditional culture-based approach, many important protein antigens may be missed during the discovery process. Adopting reverse vaccinology as the discovery approach, the laboratory validation commences with an unbiased list of all potential antigens that can be expressed by the pathogen, irrespective of life cycle stages and environmental stimuli [1] .
Despite the great potential of reverse vaccinology, it needs to be emphasized that generating lists of vaccine candidates is not trivial. The overall concept of the reverse vaccinology approach that starts with a genome and ends with a list of vaccine candidates is straightforward. However, for a researcher who intends to follow this approach for the first time, determining the computational requirements of the many intervening stages between the start and end is not immediately apparent. Furthermore, once these requirements for the stages have been determined, the next task is to find appropriate existing tools to complete each stage. There is an ever-increasing plethora of bioinformatics tools and databases. Determining which tools and databases are appropriate, as well as how to use these tools and interpret the output, is a time-consuming and overwhelming task. Currently, there is no one document in the literature that comprehensively encapsulates the insilico vaccine discovery stages for a researcher to follow.
In this article, a framework for an in silico pipeline, based on the principle of reverse vaccinology, is presented as a guide to generating a list of all potentially antigenic proteins for downstream laboratory investigations. More specifically, the present article reviews and suggests freely available bioinformatics programs that can complete each explicit stage of an in silico vaccine discovery pipeline.
PIPELINE OVERVIEW
As a proof of concept, a vaccine discovery pipeline was constructed and evaluated using data from the eukaryotic pathogen Toxoplasma gondii, which is an important model system for the phylum Apicomplexa [8] [9] [10] . The focus here, however, is on the construction of the pipeline, and no attempt is made to propose scientific findings for T. gondii, as it is beyond the scope of the present article. Despite the similarity of eukaryotic pathogens, realistically there can be no 'off-the-shelf' pipeline for vaccine discovery that would instantly work for all pathogens. A generic pipeline, nevertheless, comprising the same linked programs can theoretically be used. The challenge from a user's perspective is that these programs critically need appropriate training sets specific to the pathogen of interest.
A pipeline here simply refers to a chain of data processing stages. Freely available bioinformatics programs are suggested for each stage described herein. An ideal objective of the pipeline is to have a seamless transition from start to end in which the output of each stage is the input of the next one. The transition between the stages can be achieved by writing simple parsing and reformatting programs. A critical aspect of these programs that tie the pipeline together is extracting the pertinent data from the stage outputs and providing logic to accept or reject the data from the pipeline. Example stage outputs are provided throughout the present article, and the parts of the output that are useful are indicated. The stage transitions in the pipeline presented were written in the Perl computer language. There were five underlying criteria for selecting the various programs used to complete each stage-public availability, operating platform, high-throughput functionality, cell type and software support. Each criterion is now described in more detail: (i) public availability-the program had to be freely downloadable and have stand-alone capability and (ii) type of operating platform-the numerous programs potentially available can be classified into three platform categories: web interface, Microsoft Windows and Linux. The web interface programs are by far the most prevalent because of their immediate accessibility (i.e. no installation) and ease of use. However, processing enormous amounts of input is currently unproductive through web interfaces. Only Linuxsupported programs were chosen because Linux is becoming an international standard for academia and research. Also, although it would have been highly desirable to select the best programs irrespective of the category, it made for an extremely difficult, and perhaps unwarranted, technical challenge of trying to integrate three platforms to achieve the goal of seamless environment; (iii) high-throughput functionality-the programs need to process large numbers of input in a timely manner. What constitutes processing completion in a 'timely manner' is of course debatable; (iv) cell type-the algorithms for programs specifically designed for prokaryotic cells are, for the most part, inappropriate for eukaryotic cells and vice versa. Hence, only programs specific to eukaryotic organisms are used in the pipeline and (v) maintained and supported-ideally the program should have documentation and contact support for bug fixes and enhancements, and most importantly perform consistently without errors. This criterion was only partially fulfilled for most programs.
To summarize, the programs chosen were standalone programs for eukaryotes that could be freely downloaded, enable high-throughput processing and execute in a Linux environment. Figure 1 shows a schematic of the vaccine discovery pipeline based on reverse vaccinology. The pipeline can be conceptually broken into four interrelated tasks: creation and maintenance of a vaccine candidate list, predicting antigens using bioinformatics specialized tools, homology searches in specialized databases and comparative genomics. Table 1 shows the proposed bioinformatics programs and resources used in the presented pipeline. These programs were chosen because they fulfil each of the five selection criteria.
The outputs from many pipeline programs are simply statistical predictions. In theory, experimentally validated data are required to verify these predictions. In addition, training sets for prediction programs rely heavily on proven data. A difficulty for the pipeline is that the majority of genes and proteins within digital biological resources lack experimentally validated annotation. Finding credible proof is a major challenge. Faced with this uncertainty in the reliability of data, the proposed solution is to commence the pipeline with a pool of all known proteins that can be found in digital biological resources, irrespective of proof for their existence. The intervening pipeline stages then endeavour to prove or disprove the existence of these proteins and their likelihood to be antigenic. The intervening stages, to be described in the following sections, are as follows: creation and maintenance of the vaccine candidate list, prediction of proteins encoded in the target genome, prediction of subcellular location, prediction of excretory-secretory antigens, prediction of transmembrane proteins, posttranslational modification (PTM) prediction, epitope prediction, determination of protein function using homology searches, search of databases specific to immunology and comparative genomics.
There are essentially only two types of data flowing through the pipeline: nucleotide and protein sequences. The underlying task of the pipeline programs is to find meaningful patterns, motifs and signals within the sequences. Figure 2 shows a schematic of the data flow. In the absence of experimentally derived protein sequences, the first mandatory stage of the pipeline is to predict genes from a nucleotide input to deduce protein sequences. Obtaining quality protein sequences from this first stage is absolutely critical, as all subsequent stages rely on protein sequences as the primary input. Following the first stage, there is no strict order in which the prediction programs must be executed. The general theme throughout the pipeline is predictions, and the pipeline programs are used to gather evidence to substantiate these predictions and to ultimately finish with a final list of proteins most likely to be antigenic. The final output presented to the user is a list of protein sequences in a FASTA format and ranked in accordance to a score. The sequence identifiers are either existing UniProt IDs or novel IDs. The proteins at the top of the list are expected to make the best vaccine candidates for validation in the laboratory.
The greatest challenge facing the pipeline is ascertaining from an in silico perspective whether the proteins in the final output are useful as vaccines. No perfect predictive method is yet available. Whether a protein from a particular pathogen is immunogenic can only be realized in the context of the defined host. That is, a protein is only immunogenic if the immune system of the host responds to it. The generated list of target vaccines requires extensive downstream analysis, beyond the scope of the computational pipeline, including recombinant expression and purification of proteins and testing for immunogenicity in animal models. 
CREATION AND MAINTENANCE OF THE VACCINE CANDIDATE LIST
The first proposed stage of the pipeline is the collation of all proteins associated with the target pathogen from all possible online resources. This pool of proteins is then ranked in accordance with current evidence for each protein's existence. For instance, a protein is assigned a high rank if the source of the protein is from a mass spectrometry experiment. The pool of proteins constitutes a hypothetical proteome of the target pathogen and is a subset of an unknown-sized proteome. This hypothetical proteome is in effect a dynamic vaccine candidate list. Bioinformatics tools are used at each stage of the pipeline to gather evidence and re-rank the candidate list in accordance to a score. In the presented pipeline, the initial vaccine candidate list for T. gondii comprised all non-redundant proteins from the Universal Protein Resource Knowledgebase (UniProtKB at http://www.uni prot.org/) and all proteins found in the National Center for Biotechnology Information (NCBI at http://www.ncbi.nlm.nih.gov/) protein database but not in UniProtKB. Non-redundant proteins imply that all identical protein sequences from the same species are represented in a single record, and protein products encoded by one gene in a given species are also represented in a single record. In silico vaccine discovery for eukaryotic pathogensScoring the vaccine candidates A scoring system for the evidence is needed to re-rank the vaccine candidates after the completion of each stage of the pipeline. Scoring, nevertheless, is extremely complex and, to a certain degree, subjective, as an interpretation of the reliability of the gathered evidence is required. The role of the pipeline is essentially to score all protein sequences associated with the target pathogen (regarded here as the vaccine candidate list) in accordance with evidence that they are either surface components or are secreted. This evidence criteria are based on an a priori held hypothesis that a protein that is either external to or located on, or in, the membrane of a pathogen is more likely to be accessible to surveillance by the immune system than a protein within the interior of a pathogen [11] . The pipeline programs generate predictions that provide circumstantial evidence in an output text file. The challenge is to derive from each output an appropriate score to rank the protein within the vaccine candidate list. The complexity for an overall scoring system for the pipeline occurs because the pipeline programs have substantial differences in their prediction accuracy, internal scoring and type of formatted output. The question that arises is how reliable are the predictions and what values from the output can be used to score and rank the predictions. There are fundamentally two aspects that need to be considered: the overall accuracy of the program and the accuracy of an individual prediction. The degree of accuracy of most of the pipeline programs is primarily governed by the quality of training data. Nonetheless, a typical program accuracy can be taken from published articles, but ideally, the accuracy can be determined when the program is tested using protein sequences, desirably from the target pathogen, for which the correct prediction outcome has already been experimentally determined. For each individual prediction, a value representing accuracy or a perceived reliability or a type of score is shown in the program outputs. This value can be used to rank the program predictions. Normalization of the values may be required to produce a specific statistical property that can be used as a standard score. A standard score from each pipeline program can then be added to an accumulating score for each protein in the vaccine candidate list. As each pipeline program has a different prediction accuracy, it is proposed that the standard score is weighted by the accuracy of the program. The high-scoring proteins are expected to be the most useful vaccine candidates. A judicious threshold score can be adopted to select proteins for laboratory validation.
To illustrate the proposed scoring method, and at the same time highlight the complexities of scoring in general, the output shown in Figure 3 from the program WoLF PSORT (described later in detail in section 'Prediction of Subcellular Location') is used here as an example. The predicted subcellular location is shown for only three protein sequences, but in practice, all proteins associated with the target pathogen need to be processed. WoLF PSORT uses a weighted k-nearest neighbour classifier and classifies proteins into 12 localization sites. Only the sites of extracellular (extr) and plasma membrane (plas) are of interest to the pipeline. The values in Figure 3 indicate the number of nearest neighbours, i.e. proteins in the WoLF PSORT training data that have the most similar localization features to the query. The assumption is that the more neighbours that have the same localization then the more likely the prediction is correct for a particular site. For example, seq3 in Figure 3 has 31 of 32 neighbours Figure 3 : Typical output from WoLF PSORT. Information about each protein sequence is displayed on separate lines (only three sequences are shown). Each field along the line contains a localization class and a score separated by a comma. There are 12 localization classes that also map to Gene Ontology (GO). The localization classes in the output are abbreviated to four-letter codes, with dual localization denoted by joining the four-letter codes with an underscore character. Protein 'seq1' has six candidate sites listed in descending order of likelihood based on a score. The most likely site is extracellular (extr) and plasma membrane (plas), i.e. there is dual localization with a score of 11.5. The plasma membrane (on its own) is the next most likely site, followed by extracellular, endoplasmic reticulum (E.R.), lysozyme (lyso) and finally peroxisome (pero).
(97%) with a similar localization feature of extracellular location. It is debatable whether one could state that this prediction is 97% accurate, but based on the former assumption, the predictions (i.e. the sequences) can be ranked thus-seq3 (with a score of 97%), seq2 (78%) and seq1 (36%). In practice, all sequences with either 'extr' or 'plas' as one of the localization features are scored irrespective of whether the site has the highest number of nearest neighbours. In other words, only sequences that do not have 'extr' or 'plas' are assigned a score of zero. The creators of WoLF PSORT estimate sensitivity and specificity of 70% when predicting plasma membrane and extracellular locations [12] . A slightly lower accuracy was observed when evaluating WoLF PSORT for the proposed pipeline. Subcellular locations were correctly predicted for 64% of the test protein sequences. Therefore, the final scores from WoLF PSORT are weighted by 64% (e.g. seq3 weighted score ¼ 62%). The weighted scores are added to an accumulative score of the associated proteins in the vaccine candidate list. To reiterate, each pipeline program has a different type of output, and therefore, the method for obtaining the required standard score is different and subjective.
Appropriate scoring is one of the most critical aspects of the pipeline, as it provides the only indication before experimental testing of how 'likely' the proteins predicted by the pipeline will be suitable as vaccine candidates. The scoring system currently proposed is acknowledged to be far from ideal, and its improvement remains a challenge. Alternative scoring systems using machine learning are suggested in the 'Discussion' section.
Prediction of proteins encoded in the target genome
Predicting proteins encoded in the target genome has two main objectives. The first is evidence gathering to support the existence of proteins already in the vaccine candidate list, and the second is to identify novel proteins to be added to the list. To predict proteins, the first challenge is to computationally find genes within the genome-but more specifically, identification of putative exons in unannotated nucleotide sequences so that the encoded protein(s) may be deduced.
Research into finding genes in anonymous genomic sequences has been going on for >20 years, and there is an abundance of the literature [13] [14] [15] [16] [17] [18] [19] . There are three different methods to computational gene finding: ab initio (or intrinsic) [15] , evidence based (or extrinsic) [20] and genome sequence comparison [21] . All three methods to some degree are used in the pipeline to provide evidence of a protein's existence and to discover novel proteins, rather than their typical use of genomic annotation.
Ab initio gene finders attempt to identify genes from DNA sequence alone. This has proved to be an immense challenge [22] . The best achievable approach from an ab initio perspective is to use statistical models to predict genes and their exon-intron structures. There are numerous gene prediction programs freely available that attempt to meet the challenge. At the time of writing, >60 could be found in the literature, though many of the published URLs were no longer valid. Table 2 shows a small sample of the most common gene finders. The disparity in their gene predictions for the same DNA sequence shows that the gene-finding challenge is still to be overcome [19] .
The challenge from a user's perspective is which gene prediction program to use. The most judicious approach is to use several gene finder programs and feed a consensus of the gene predictions into the next stage of the pipeline. The gene finders chosen for the pipeline had to meet the previously described five selection criteria and have either a readymade trained model or functionality to create one for the target pathogen. Four ab initio gene finder programs fulfilled the criteria: GeneMark.hmm [33] , AUGUSTUS [38, 39] , SNAP [18] and Glimmer-HMM [37, 45] . All gene finders used in the pipeline use a variation of hidden Markov models (HMMs) [46] . An HMM is used to statistically model structure of DNA sequences, and each gene finder has its own complex internal algorithm to decode the HMM into gene predictions [47] . For details on how these programs work refer to the following references: [18] , [33] , [37] and [38] .
Evidence-based gene finders (also commonly referred to as expression-based or extrinsic predictors) use evidence such as DNA copies of messenger RNA (complementary DNA) and/or proteins and/or expressed sequence tags (ESTs) [47] . They work by aligning evidence sequences, ideally from different types, to the pathogen genome based on sequence similarity. In effect, the evidence constitutes combined exons, and the alignment to genome attempts to re-introduce introns into the evidence to determine the exon-intron structure of the gene. An important advantage of an evidence-based approach over an ab initio one is that irrespective of the preciseness of the predicted exonintron structure, a similarity match is enough to provide proof of the existence of a gene (with the caveat that the evidence is correct). An obvious limitation of an evidence-based approach is that no gene will be found if there is no evidence. Many genes are expressed only under specific conditions or at a virtually undetectable level.
Gene finder programs that are strictly evidence based were designed specifically for genomic annotation. With respect to the pipeline, gene finders are used as an aid to prove or disprove a protein's existence. Aligning a messenger RNA or protein to a genome provides no additional evidence that the protein exists (this is not surprising, as they are in themselves the evidence for the protein's existence). The evidence-based gene finders are only of benefit to the pipeline with ESTs. If given ESTs, the pipeline uses two evidence-based gene finders called BLAT [48] and GMAP [49] . These programs align the ESTs to the genome and predict exon locations-including a prediction of the number of exons per gene. Both programs output the exon information in a PSL format (a format specific to BLAT). An additional novel program is required to extract the relevant data from the PSL files and to concatenate nucleotide sequences from each exon member of a gene. The concatenated exons form the query for BLASTX against the vaccine candidate sequences. In summary, ESTs provide additional evidence for either the existence of a known protein in the vaccine candidate list or as a novel protein to be added to the list. As is the case for all evidence gathering processes in the pipeline, additional evidence alters protein ranking in the vaccine candidate list.
Genome sequence comparison methods use sequence conservation to help identify coding exons. The underlying principle of the method is comparing anonymous genomic sequences from the same or different organisms, under the assumption that regions conserved in high-complexity sequences will tend to correspond to coding exons from homologous genes [50] . In other words, the conserved regions between related organisms are more likely to be coding, and conversely, the divergent regions more likely to be non-coding. SLAM [51] , SGP2 [50] and TWINSCAN [21] are three examples of gene prediction programs using patterns of conservation between genomes to help identify coding regions and splice sites. N-SCAN [40] , a descendant from TWINSCAN 2.0, which is in turn descended from GENSCAN [30] , is used in the pipeline. N-SCAN requires the genomic sequences of the target and informant organisms to have an appropriate evolutionary distance.
Prediction of subcellular location
The objective here is to determine where each protein in the vaccine candidate list resides in the pathogen. More formally, there is a need to computationally predict each protein's localization and in effect mimic the biological mechanism of protein sorting [52] by which a protein, after its encoding and synthesis, is transported to the appropriate position in or outside the pathogen. The main determinant of a protein's localization is the protein amino acid sequence [12] . In effect, the sequence contains a delivery address. Many programs have been developed to predict subcellular locations of proteins [53, 54] , and some of these programs can be found at http://www.ncbi.nlm.nih.gov/ CBBresearch/Lu/subcellular/. Most programs are web based and do not fulfil the high-throughput requirements for the pipeline.
WoLF PSORT (see Table 1 for URL) is an extension of the PSORT II program and is used by the pipeline for the prediction of protein localization sites in the pathogen [12] . It requires as input, full-length amino acid sequences of a protein in a FASTA format. The program detects sorting signals within the sequence from which it then computationally predicts the protein's subcellular localization. A training data set is required comprising protein sequences with a known localization label. The training set supplied with the program is stated to be applicable to animals and contains 12 000 UniProt sequences [12] . Figure 3 shows a typical output from WoLF PSORT.
A point to note is that WoLF PSORT does not predict apicoplast targeting signals. An apicoplast is a non-photosynthetic plastid found in apicomplexans. There is, however, a web-based program called PlasmoAP that predicts targeting signals specific to apicoplasts [55] .
Prediction of excretory^secretory antigens
It is a requirement of the pipeline to distinguish proteins that are secreted by the pathogen. One of the most well-known sorting signals is the secretory signal peptide, which targets a protein to the secretory pathway via the endoplasmic reticulum. It is important to know that not all secretory proteins have signal peptides, or are necessarily secreted to the outside of the pathogen [54] . There are many different types of secretory signal peptides, but the most common type is the signal peptide cleaved by signal peptidase. Secretory signal peptides can be computationally predicted using machine learning techniques, such as neural networks (NNs) and HMMs [56] . The program SignalP (see Table 1 for URL) is used by the pipeline and combines two different NNs to: (i) classify each residue in the sequence as either belonging or not belonging to a secretory signal peptide and (ii) recognize the signal peptidase I cleavage site at the C-terminal end. There are also signal peptides that are not cleaved called signal anchors, i.e. a transmembrane protein with one transmembrane segment near the N-terminal of the protein [57, 58] . SignalP incorporates an HMM method to discriminate between cleaved signal peptides and signal anchors. Training data for eukaryotes, mostly derived from UniProt, are supplied with SignalP. An example of the summary output from SignalP is shown in Figure 4 .
To help endorse SignalP predictions, the program TargetP is used in the pipeline (see Table 1 for URL). NNs are also implemented by TargetP to predict subcellular locations of eukaryotic protein sequences. More specifically, it predicts the presence and length of secretory pathway signal peptides and mitochondrial targeting peptides in the N-terminal pre-sequences [59] .
Prediction of transmembrane proteins
Being exposed to the outside environment, surface membranes of pathogens are in full view of a host's immune system surveillance. Consequently, membrane molecules, including proteins spanning or anchored to the membrane, are likely to be antigenic. A transmembrane protein that spans an entire membrane has a predominantly hydrophobic domain consisting of one or multiple a-helices motifs [60] . Numerous programs to predict transmembrane helices have been developed over the past 30 years-programs such as DAS, SOSUI, SPLIT, TMAP, TMpred, TopPred 2, MEMSAT, HMMTOP, ALOM 2 and Tmpro. Moller and colleagues [61] evaluated methods for the prediction of membrane-spanning regions. The majority of programs are web servers and therefore are unsuitable for high-throughput processing.
The program TMHMM (see Table 1 for URL) is based on an HMM approach [60] and is used in the pipeline to predict transmembrane helices in all protein sequences (in a FASTA format) from the vaccine candidate list. Figure 5 shows one line of a typical output from TMHMM in a summary format.
A program called Phobius, a combined transmembrane protein and signal peptide predictor, is used in the pipeline to help discriminate between transmembrane helices and signal peptides and also add endorsement to TMHMM predictions (see Table 1 for URL). Figure 6 shows the output from Phobius in a short format.
PTM prediction
Most proteins have some PTMs, and these modifications can either affect or determine the structure and function of a protein [62] . Any of the 20 natural amino acids that build polypeptide chains can be potentially subjected to PTMs [63] . Glycosylphosphatidylinositol (GPI) anchoring is a ubiquitous cleavage and linkage PTM that anchors eukaryotic proteins to cellular membrane [64] . GPI-anchored proteins can be involved in different functions, such as recognition and signalling processes, but are of particular interest to vaccine discovery because they are exposed to the extracellular environment and hence are potential surface antigens [65] . Four GPI-anchored protein predictors are publicly available: big-PI [66] , GPI-SOM [67] , PredGPI [65] and FragAnchor [68] . Table 3 shows the algorithm(s) used and URL of the predictors. A high-throughput stand-alone GPI predictor is not yet available and so cannot be integrated into the pipeline. Figure 5 : Typical summary output format from TMHMM v2.0. Each output line shows the length (len) of the protein sequence followed by the expected number of amino acid residues in transmembrane helices (ExpAA). If the ExpAA number is >18 (a value proposed by the TMHMM creators), it is likely to be a transmembrane protein (or have a signal peptide). The output line also shows the expected number of residues in the transmembrane helices in the first 60 amino acids of the protein (First60), the number of predicted transmembrane helices (PredHel) and the predicted protein topology. The larger the First60 number, the more likely the predicted transmembrane helix in the N-terminal is a signal peptide.
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7 Y n4-19c24/25o219-238i250-269o281-302i322-342o372-391i422-439o451-476i Ymax is a derivative of the C-score combined with the S-score resulting in a better cleavage site prediction than the raw C-score alone, (iii) Smax is the 'maximum signal peptide' prediction score, (iv) Smean is the 'average of the S-score' and (v) D is an average of the 'S-mean and Y-max' score. SignalP (HMM) comprises two different scores: (i) Cmax is the maximum 'cleavage site' score and (ii) Sprob is the probability of a signal anchor (an uncleaved signal peptide). Position (pos) is the location in the amino acid sequence of the cleavage site and length of signal peptide. The 'Y' or 'N' is a yes or no indication that the sequence has a cleavage site and is a signal peptide. High scores also indicate that the sequence is a secretory protein. According to the authors of SignalP, a high D-score is the best indicator of secretory proteins [57] .
Epitope prediction
Epitopes are the minimal structure recognized by the immune system and are the principal components of subunit vaccines [69] . The current trend in vaccine development is epitope based because of its potential to be more specific, safer and easier to produce than traditional vaccines [70] . There are two types of epitopes on protein antigens: linear (or continuous) and conformational (or discontinuous). Linear epitopes are continuous stretches of amino acids in a protein sequence, whereas conformational epitopes are formed through folding of the protein bringing together discontinuous amino acid sequences to form the epitope [71] . Epitopes that are recognized by T-cells are called T-cell epitopes, and likewise, epitopes recognized by B-cells are B-cell epitopes. B-cell epitopes are either continuous (10%) or discontinuous (90%), whereas T-cell epitopes are usually continuous [71] . It is the recognition of epitopes on pathogens by T-and B-cells (and soluble antibodies) that activates the cellular and humoral immune response [11] . Many methods have and are still being developed to computationally predict epitopes [69] [70] [71] [72] [73] [74] . There are both sequence-and structure-driven [75] methods, i.e. prediction based on amino acid sequences (primary structure) as opposed to three dimensional structures. The objective at this stage of the pipeline is not specifically to identify epitopes for vaccine development but to use epitope prediction methods to provide further evidence of a protein's antigenicity. The premise is that if an epitope can be associated with a protein in the vaccine candidate list, then the protein is more likely to be antigenic. Table 4 lists some of the T-cell epitope predictors. All predictors, with the exception of CTLPred, use an indirect method that focuses on prediction of peptide binding to major histocompatibility complex (MHC) molecules. Only NetMHC, netMHCII, NetMHCIIpan and Immune Epitope Database (IEDB) from Table 4 have stand-alone packages that can be downloaded. The IEDB package was chosen for the pipeline because its downloadable Linux package (for a 32-bit system) contains a collection of peptide binding prediction tools for MHC class I and class II molecules. Included in the package are NetMHCpan and NetMHCIIpan, which are extended versions of NetMHC and netMHCII, and have been shown to perform well in two evaluation articles [76, 77] . The collection of tools is a mixture of Python scripts and Linux-specific binary files. Python 2.5 or higher is therefore a prerequisite to run the tools. These tools take as input an amino acid sequence (or a set of sequences) and determine the ability of each subsequence to bind to a specific MHC molecule. For MHC class I, the available prediction methods are as follows: artificial NN (ANN) [78] , average relative binding (ARB) [79] , stabilized matrix method (SMM) [80] , SMM with a peptide-MHC binding energy covariance matrix, scoring matrices derived from combinatorial peptide libraries (Comblib_Sidney2008) [81] , consensus [82] and NetMHCpan [83] . The consensus method is recommended by the creators of IEDB.
Prediction methods are encapsulated in two programs: predict_binding for MHC class I and mhc_ II_binding for MHC class II. The method to use in the prediction is given as a command-line parameter. Figure 7 shows an example of the command line syntax. Figure 8 shows a typical output from the MHC class I predictor using a consensus method (some columns have been deleted, and the format has been adjusted to fit output on the page).
Proteasomal cleavage and transporter associated with antigen processing binding are principal subcomponents of the antigen processing and presentation pathway. There is currently much interest in developing algorithms that integrate MHC I peptide predictions with prediction of transporter associated with antigen processing binders and proteasomal In silico vaccine discovery for eukaryotic pathogenscleavage sites, with the expectation of achieving better T-cell epitope predictions [84, 85] . The MHC II binding peptide predictions are more computationally challenging than for MHC class I, and this seems to be reflected in the inferior prediction performance of class II algorithms in comparison with those in class I [79] . In the IEDB download package, the available prediction methods for MHC class II are as follows: consensus [86] , ARB [79] , combinatorial library (unpublished method), NN-align [87] (this method is the equivalent to netMHCII version 2.2), SMM-align [88] (equivalent to netMHCII version 1.1), Sturniolo [89] (a method also used in the program TEPITOPE [90] ) and NetMHCIIpan [91] . Wang and colleagues [86] assessed MHC class II peptide binding prediction methods in 2008. The IEDB curators rank consensus as the best method, followed by NN-align, SMMalign, combinatorial library, Sturniolo and lastly ARB. The output is in a similar format to the one shown in Figure 8 , and the score is in units of IC 50 nM for all methods except for Sturniolo, which outputs a raw score (higher raw scores indicate higher affinity).
The other important arm of the adaptive immune system is the humoral response of B-lymphocytes. B-cells are able to either directly bind with an antigen through their B-cell receptors or secrete antibodies that bind to the antigen [69] . Consequently, B-cells directly or indirectly contribute to the destruction of pathogens. Predicting B-cell epitopes is extremely problematic. Sequence-and structuredriven tools for predicting B-cell epitopes do exist; however, the majority of the literature reviews evaluating B-cell epitope predictors report disappointing performances [92] [93] [94] . The current belief by some researchers is that B-cell epitopes are too complex to model in silico. This is mainly because proteins are structurally dynamic and can change their native conformation when binding to antibodies [95] .
Despite the enormity of the challenge, there are several prediction tools for B-cell epitopes (Table 5) .
Only the programs BepiPred, MIF-Antigen and DiscoTope from Table 5 can be downloaded. As all predictions from sequenced-based approaches are currently questionable, BepiPred and MIFAntigen are not used in the pipeline. Structure driven is considered by far the best approach, but prediction accuracy is strictly dependent on the availability of three dimensional data of protein structures. The primary source for structural data is the Protein Figure 8: Typical output from IEDB MHC I peptide binding predictor. Beginning at the start amino acid (numbered 1) of each sequence (denoted by #), a test subsequence of a specific peptide length (e.g. PepLength ¼ 9) is created. For example, sequence ¼ MSMEGDRPS and is located from amino acids 1 to 9 on sequence input #1. The subsequence is scored in units of IC 50 nM for binding affinity against the MHC allele HLA-A*02:05, using different prediction methods. That is, scores are calculated for each amino acid at each position in the subsequence, which are then added to yield the overall binding affinity. In this example, method NetMHCpan was used because no previous method was available for the allele-length combination. However, the output could in theory contain scores from multiple methods if the method was available for the allele-length combination. The next test subsequence is 'SMEGDRPSG' from amino acids 2 to 10 on sequence input #1 and is scored against the same MHC allele, and so on. The affinity of the MHC allele and subsequence binding is greater the lower the IC 50 value. The program creators propose a rough guideline for interpretation: peptides with IC 50 values <50 nM are considered high affinity, <500 nM intermediate affinity and <5000 nM low affinity.
Data Bank (PDB). The PDB data can be downloaded, or a tool can be written to communicate with the PDB resources using a protocol specification for exchanging information with web servicesSimple Object Access Protocol (SOAP) or REpresentational State Transfer (RESTful). There is currently limited structural data in PDB available for most proteins from eukaryotic pathogens. Despite the limited data, the program DiscoTope [104] is used in the pipeline to gather further evidence of a protein's antigenicity. To reiterate, the premise is that if an epitope can be associated with a protein in the vaccine candidate list, then the protein is more likely to be antigenic. Version 1.1 of DiscoTope (current web server version is 1.2) can be downloaded and installed in a Linux environment. The input required for DiscoTope is a file containing PDB IDs of proteins to be processed. A typical output from DiscoTope is shown in Figure 9 .
Determination of protein function using homology searches
Determining the function of a protein provides an important clue to antigenic potential. Mapping gene ontology (GO) terms to proteins in the vaccine candidate list is considered an important step towards ascertaining protein function. GO terms for immune system-specific functions, processes and cellular components can be found associated with gene products. Even so, the quantity and quality of immunology GO terms currently limit the level of interpretation that can be achieved. A challenge for the pipeline is that the GO terms are not necessarily indicative of determining whether a protein is potentially antigenic, .i.e. the clue to antigenic potential can be obscurely found within the term. For instance, a GO term (GO: 0006955) is 'evasion or tolerance of immune response of other organism involved in symbiotic reaction'. A novel program is required to make a link between GO terms and immunological significance. A novel Perl script for the pipeline searches for user-defined keywords within the text of the GO term. Ideally, the keywords should be compiled by a specialist in the fields of immunology and vaccinology. Function-specific data on the target pathogen may be limited. Therefore, homologues to the proteins in the vaccine candidate list are a viable alternative. A client web-based program called Blast2GO [106] can essentially map sequences from homology searches to GO terms. To fulfil a high-throughput requirement, the pipeline uses a specific Java version of Blast2GO called B2G4Pipe that can be downloaded from the Blast2GO website (see Table 1 for URL) and installed in a Linux environment. To run B2G4Pipe, an internet connection is required to the Blast2GO database. Alternatively, the Blast2GO database can be downloaded, and built locally using MySQL Server. A tab-separated output file (.annot) is generated containing two columns: sequence name and GO IDs. The GO IDs need to be mapped to GO terms contained in the MySQL GO database. A standard query language (SQL) dump of the GO database can be downloaded and rebuilt with MySQL Server. Alternatively, remote access to the GO database can be achieved via an application programming interface provided by go-perl and go-db-perl scripts downloaded from the GO website.
Search of databases specific to immunology
Databases created specifically in an immunological context are available online. Figure 9 : Typical output from DiscoTope version 1.1. The tab-delimited columns are as follows: chain ID (if known), residue number; three-letter amino acid code, contact number (i.e. the number of C-alpha residues within the user-defined contact distance [105] ), proximity sum (i.e. initial score without contact number taken into account) and final score (i.e. a simple weighted sum of the contact number and a sum of sequentially averaged epitope log-odds ratios of spatially proximate residues). The higher the final score, the greater the probability a residue is part of a B-cell epitope. A user-definable threshold can be applied, and any residue with a final score greater or equal to the threshold is denoted by the symbol '<¼B' in the output. This symbol highlights the residues that are predicted to part of an epitope.
functional databases that focus on the mechanics of cellular and humoral immunology. All databases are accessed online through websites, and varying types of immunological data are available. However, Table 6 only shows whether the database, given a protein sequence as a query, can potentially match either a T-or B-cell epitope, or an antigen. All databases, except IEDB, can neither be downloaded nor remotely accessed and are therefore unsuitable for the pipeline. IEDB is a National Institute of Health-funded database. The database contains experimentally determined immune epitopes, which includes characterized records on T-and B-cell epitopes, MHC binding and MHC ligand elution experiments. The data are derived from the literature in PubMed containing epitope-related experiments and from direct submissions from investigators experimentally generating epitope-related data [107] . The IEDB website provides the option to download the schema, tables or the entire database in either XML or MySQL formats. Novel SQL scripts are required to extract relevant information from the downloaded local IEDB.
COMPARATIVE GENOMICS
Research in comparative genomics is rapidly becoming more prevalent and important with the everincreasing number of genomes being sequenced. Comparative genomics is basically the comparison of genomes within and between species or strains [108] , with the general aim to collate information on similarities and differences. Table 7 shows some tools for comparative genomics.
Comparative genomics works on the principle that functional sequences are more similar across species than non-functional sequences, as changes in functional regions often reduce the fitness of the organism [109] . The pipeline uses a comparative genomics approach through the program MUMmer to identify core genes and subsequently those proteins in the vaccine candidate list that are less likely to be pathogenic. Core genes are genes that are conserved among strains. The more strains that can be compared, the greater the certainty of these core genes. The genes likely to encode for antigenic proteins (i.e. those that are members of the so-called dispensable genes and are absent in at least one strain) cannot be derived directly from the MUMmer output. Figure 10 shows a typical output from MUMmer when comparing two genomes.
DISCUSSION
The in silico approach to vaccine discovery is to identify potential protein antigens entirely from digital biological resources. Generating data for these resources is perhaps no longer a stumbling block in the high-throughput era; instead, it is the validation and interpretation of data that limit progress. In this article, only the first part of a much longer vaccine discovery pipeline based on '-omics' technology was presented. That is, only the genomics, transcriptomics and proteomics of the pathogen were exploited here. A future extension to the pipeline would entail host-pathogen-specific -omics such as immunomics. Sette and Rappuoli [110] discuss the incorporation of a cellular immunity dimension into reverse vaccinology.
The development of bioinformatics tools is a primary reason why in silico vaccine discovery is feasible. However, the tools in themselves present many technical challenges. At the onset, there are an overwhelming number of bioinformatics tools available online to choose from. In one sense, the post-genomic era has experienced a gold rush, and it is perhaps equally difficult for researchers to find the 'gold' standard bioinformatics tools among so many. Without actually running the tools, it is difficult to determine which tool is best for the task at hand. Occasionally, program evaluation articles can be found but become quickly outdated, as new tools are regularly emerging. Often, the methods behind the programs are hidden from the user, leading to uncertainties about their confidence, accuracy and information content [111] . Conversely, the methods that are written in the literature are too technically and computationally sophisticated for a biologist to fully understand. It is of course the expertise of a biologist who in effect converts a program output into scientific findings worthy of publication. To a certain extent, there is a black box mentality in which the interpretation of the output is made without necessarily knowing how the output was derived.
The quality and quantity of data are arguably the most important factors that determine the success or failure of in silico vaccine discovery. No matter how accurate the bioinformatics tool might be, the computer adage 'garbage in-garbage out' holds true. Many algorithms of the programs used in the pipeline require training data, and hence, these data-driven programs are only as accurate as the data used to train them [11] . Ideally, experimentally validated data should be used in the training data, although even experimental data have the potential to be incorrect, for example, flawed interpretation of the results or simply experimental errors. Also, sequences in well-curated databases, such as UniProt, are not necessarily error free. The point to be taken here is that biological data, irrespective of its source, should not always be taken at face value.
The challenge to improve the current proposed scoring system of the vaccine candidates is still to be resolved. To recap, the presented vaccine candidate list comprises all protein sequences, associated with the target pathogen, with a single score that attempts to encapsulate all evidence generated by the pipeline programs. The evidence (i.e. the score) from each program could collectively be considered to improve the scoring. Figure 11 shows an extract from a compiled file that contains selected output values (i.e. the evidence) from the pipeline programs. For brevity, the output values from only five pipeline programs and five proteins are shown.
Each line of output values in Figure 11 defines a score profile for a particular protein. It is conceivable that there may be an informative pattern, perhaps hidden to a human observer, within the score profiles that is specific to the most useful vaccine candidates. Applying data mining and in particular machine learning methods [e.g. decision trees, random forests (RF) and SVMs] can effectively find these patterns, if they exist. For this approach to work, biological domain experts would initially be required to indicate (label), within a set of proteins (i.e. a training set), the proteins that they believe to be the most probable vaccine candidates and ideally provide a probability score. The great advantage with a semi-supervised machine learning method [112] is that it can use the large number of unlabelled proteins to improve the learning task (the ability to find patterns) when only a few probable proteins are labelled. In effect, only a small number of labelled proteins along with all the unlabelled proteins are required to train an algorithm. Such a semi-supervised learning algorithm would be capable of learning and making decisions from hidden patterns within score profiles to ultimately calculate the probability that a protein is a promising vaccine candidate.
As a proof-of-concept that the pipeline fulfils its intended purpose, and that is to predict 'likely' vaccine candidates, we have input amino acid sequences for which the correct prediction outcome was already known. For example, the literature describes many proteins that have been experimentally shown to be 'likely' vaccine candidates. Our premise is that if the pipeline can successfully identity these experimentally acknowledged vaccine candidates, then we can have confidence that other proteins identified by the pipeline are likely to be useful vaccine candidates. We input, into the pipeline, amino acid sequences of 29 proteins that have been experimentally shown to be potential vaccine candidates for toxoplasmosis and neosporosis. For brevity, only 13 of the 29 are shown in Table 8 along with a publication reference to the relevant study. To classify and score the proteins, we used the pipeline output values (similar to output shown in Figure 11 ) and a RF model. The results are shown in the last two columns of Table 8 . Of the 29 proteins, 21 were classified 'YES' for vaccine candidate by a RF classification model, and 20 of the 21 had scores >50 as determined by a RF regression model. The proteins with a 'NO' classification or a score <50 were proteins that a study [122] identified to be biologically reactive antigens when screened for immune potency using CD4 þve T-cell lines. However, these proteins in question are neither secreted nor membrane associated. We conclude that given complete protein sequences, our proposed in silico pipeline will, with a high degree of accuracy, identify those proteins that are either secreted or membrane associated, and as a consequence, will generate a list of proteins worthy for laboratory validation.
There are limits to what in silico vaccine discovery can achieve, yet there are also immense opportunities for exploiting its potential, and it has a bright and exciting future. Genome sequences lie at the heart of in silico vaccine discovery. The falling cost and rapid improvements in sequencing technology will spur on sequencing of genomes at an unprecedented level. It is not inconceivable to expect that in the near future, we will readily have available a genome sequence for any strain that has been isolated and have multiple genome sequences of the same strain. Meanwhile, the cost of RNA sequencing is now considered affordable, and it is expected that extensive amounts of data will soon be generated. In silico vaccine discovery is not an attempt to replace experimental work but is a powerful complementary approach to greatly help biologists save time and effort. It is likely that in silico methods will grow in importance as computational techniques inevitably advance, and a gradual paradigm shift will move the importance further from the time-consuming and expensive culture-based methods to high-throughput in silico methods. Finally, and certainly the most important, in silico vaccine discovery will clearly contribute to the prevention and control of some of the most devastating and challenging diseases, such as malaria, that we currently face.
CONCLUSION
In this article, a framework for a pipeline is presented as a guide for high-throughput vaccine candidate discovery for eukaryotic pathogens, such as apicomplexans. Each pathogen presents unique challenges and opportunities. The preliminary step would be to collate enough quality data and create training sets. Creating optimal training sets is an art in achieving a balance between accuracy and overtraining. The pipeline is based on the principle of reverse vaccinology and is constructed from freely available bioinformatics programs. Each proposed program runs in a command-line mode under a Linux/ UNIX environment and requires fine tuning of command-line parameters. The underlying task of the pipeline is to commence with a pool of all known and predicted proteins for the target pathogen, i.e. the pool constitutes a dynamic vaccine candidate list, and then use bioinformatics tools to gather evidence to finish with a ranked list of all proteins based on an appropriate scoring system. It is expected that the list will be fine tuned by an experienced immunologist by manually consulting online web servers such as the Kyoto Encyclopedia of Genes and Genomes and PubMed to gather additional information. The final vaccine candidate list provides the starting impetus for downstream laboratory investigations.
Key Points
Eukaryotic pathogens cause some of the most damaging and difficult to treat diseases of humans and livestock. Reverse vaccinology is anin silico vaccine discovery approach that can predict all potential antigens that can be expressed by the pathogen, irrespective of life cycle stages and environmental stimuli. There are bioinformatics programs freely available that can complete each stage of an in silico vaccine discovery pipeline. This article encapsulates the in silico vaccine discovery stages for a researcher to follow.
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